Dublin, Aug. 02, 2022 (GLOBE NEWSWIRE) -- The "Pharmacovigilance World 2022" conference has been added to ResearchAndMarkets.com's offering.
With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in recent years, which is apparent with the excess documentation of adversities and drug toxicities. In this context, drug safety and pharmacovigilance has emerged as a dynamic clinical and scientific discipline to provide adequate information and ensure health safety by the joint interaction of doctors and patients in choosing appropriate treatment method and drug.
However, evidence suggests though avoidable, the adverse drug reactions (ADRs) to medicines continue to be the bigger life risk. In England, ADR was responsible for up to 6% of hospital admissions, carrying mortality of 2% and costing the NHS £466 million per annum (€654 million, US$ 602 million) in 2004. In some countries, ADR is ranked among the top 10 leading cause of mortality.
The concept of drug safety and pharmacovigilance has evolved considerably and is highly necessary to keep the severity of ADR under check. In order to prevent or to reduce harm to patients and improve public health, it is vital to develop and practice mechanisms for evaluating and monitoring the safety of medicines in clinical use. Pharmacovigilance brief the potential implications of such trends on the evolution of the science.
However, these days it is confronting issues to develop a better health care system in this global pitch. Some of the major challenges include globalization, web-based sales, and information, broader safety concerns, public health versus pharmaceutical industry economic growth, monitoring of established products, developing and emerging countries, attitudes and perceptions to benefit and harm, outcomes and impact, etc.
The Pharmacovigilance World 2022 conference will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug Safety, and how it contributes to public health. It will also allow all its participants to interact with the experts, and discuss the various developments, challenges faced, and innovations in the field.
The conference will bring forth the participants and the representatives from various fields of pharmacovigilance and drug safety under a common umbrella, and will provide them an opportunity to network with various industry professionals including pharmaceuticals, biologics, devices, CROs and PV service providers.
Conference Streams Include
Global PV & Methodologies
Data management & Analytics in PV
PV Automation, AI & Machine Learning
Safety Signals & Management
Patient Centric Drug Safety
Quality & Compliance
Medical Devices Safety
Adverse Drug Reactions
Pharmacovigilance and globalization
Pharmacovigilance in a pandemic world
Women and child health care medicines and pharmacovigilance
Patient-centric approaches in PV
Pharmacovigilance legislation and regulations
Harmonization and pharmacovigilance
Advanced therapeutic techniques and pharmacovigilance
Pharmacovigilance and data management and eudravigilance
Post-marketing surveillance in pharmacovigilance
PV regulations and challenges
Benefit-risk management strategies
Risk management and minimization
Risk Evaluation and Mitigation
Adverse drug reactions reporting
Signal detection and post-authorization safety
Good Pharmacovigilance Practices
Innovative approaches to drug safety
Strategies to improve PV
Real-World Evidence in PV
Big data and AI in pharmacovigilance
Pharmacovigilance Workflows with AI & Automation
Other emerging technologies in PV
Robert Massouh, Director - Risk Management Product Lead, Pfizer
Robert Di Giovanni, Global Project Safety Lead, Novartis
Raj K Bhogal, Senior Director, R&D Audits & Inspections, Jazz Pharmaceuticals
Rodrigo Ruiz, Senior Manager, Patient Safety, Bristol-Myers Squibb
Ajinkya Inamdar, Director, Vaccines Global Safety Strategy and Risk Management, The Janssen Pharmaceutical Companies of Johnson & Johnson
Maria Maddalena Lino, Safety risk Lead Director, Pfizer
Michael Von Forstner, Global Head of Clinical Safety and Pharmacovigilance, Biogen
Laura Arce Mora, Country Safety Lead, Pfizer
Maria De Los Angeles Hernandez Loli, Patient Safety Lead Cluster Ecuador - Peru, Boehringer Ingelheim
Valentina Mancini, Director Pharmacovigilance, EU and UK QPPV, Shionogi
Victoria Bartasek, Senior Associate Director, Global Pharmacovigilance Operations, Boehringer Ingelheim
For more information about this conference visit https://www.researchandmarkets.com/r/om47w
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900